FeesSafety
Pluang+

argenx to acquire Forte Biosciences for $2.2B, adding novel anti-CD122 antibody FB102 to its immunology pipeline.

Company Fundamentals
27 Jul 2026, 08:00 WIB
GlobeNewsWire
View Source
Bullish
argenx to acquire Forte Biosciences for $2.2B, adding novel anti-CD122 antibody FB102 to its immunology pipeline.

argenx SE announced it will acquire Forte Biosciences for approximately $2.2 billion in cash, paying $77 per share. This acquisition adds Forte's lead drug candidate FB102, a first-in-class anti-CD122 antibody with promising Phase 1b results in vitiligo and celiac disease, to argenx's immunology portfolio. The deal strengthens argenx's position in autoimmune disease treatment by expanding its pipeline with a novel approach targeting T-cell and NK-cell activity. The acquisition is expected to close in Q3 2026, subject to regulatory approvals and customary conditions.

More News

Raymond James upgrades Charles Schwab to Strong Buy as client assets hit $13.27T in Oct 2026

Raymond James upgrades Charles Schwab to Strong Buy as client assets hit $13.27T in Oct 2026

Raymond James upgraded Charles Schwab to Strong Buy following strong growth in October 2026. Client assets rose 12% year over year to $13.27 trillion, with core net new assets surging 50% to $66.5 billion, a record for the month. Schwab also opened 4...

Analyst Insights
Bullish
1 hour ago
SDVerse named CES Innovation Awards 2027 Honoree for AI-powered automotive software marketplace.

SDVerse named CES Innovation Awards 2027 Honoree for AI-powered automotive software marketplace.

SDVerse, a B2B automotive software marketplace founded by General Motors, Magna, and Wipro, was honored with a CES Innovation Award 2027 in the Enterprise Tech category. The platform uses AI and standardized technical data to help automakers and supp...

Others
Bullish
1 hour ago
Progressive Ventures closes $12.24M fund to back early-stage B2B AI startups before Demo Days.

Progressive Ventures closes $12.24M fund to back early-stage B2B AI startups before Demo Days.

Progressive Ventures, a Silicon Valley venture firm, has closed its first fund at $12.24 million to invest in early-stage B2B AI and SaaS startups from programs like Y Combinator and Berkeley SkyDeck before their Demo Days. The fund has already backe...

Others
Bullish
1 hour ago
Virbac to present at Jefferies Global Healthcare Conference in London on Nov 18, 2026

Virbac to present at Jefferies Global Healthcare Conference in London on Nov 18, 2026

Virbac announced that CEO Paul Martingell and CFO Habib Ramdani will present and hold a Q&A session at the Jefferies Global Healthcare Conference in London on November 18, 2026. Investors and interested parties can watch the live webcast on Virbac's ...

Market News
Neutral
1 hour ago
JPMorgan upgrades Millicom to Overweight as it plans $1.7B Entel Peru acquisition and bond buybacks.

JPMorgan upgrades Millicom to Overweight as it plans $1.7B Entel Peru acquisition and bond buybacks.

JPMorgan upgraded Millicom International Cellular to Overweight with a $105 price target, citing strategic moves including a $1.714 billion acquisition of Entel Peru and bond tender offers. Millicom is buying Entel Peru with local financing and cash,...

Analyst Insights
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App